TipRanks
Advertisement
Advertisement

CRSP Stock Latest News

Crispr Therapeutics Expands Into Autoimmune Neurology With New CTX112 Trial
Company AnnouncementsCrispr Therapeutics Expands Into Autoimmune Neurology With New CTX112 Trial
2h ago
CRSP
CRISPR Therapeutics Appoints Andrew Silver as New CFO
PremiumCompany Announcements
CRISPR Therapeutics Appoints Andrew Silver as New CFO
3d ago
8K
CRSP
Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed
PremiumThe Fly
Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed
3d ago
CRSP
Amprius, Viking, Regeneron, Ionis, Crispr Trending With Analysts
PremiumWeekend Updates
Amprius, Viking, Regeneron, Ionis, Crispr Trending With Analysts
5d ago
AMPX
CRSP
Crispr Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Crispr Therapeutics management to meet with Piper Sandler
7d ago
CRSP
Crispr Therapeutics initiated with a Neutral at UBS
PremiumThe FlyCrispr Therapeutics initiated with a Neutral at UBS
8d ago
CRSP
Cathie Wood Just Sold $3.36M in META Stock. Here’s What She Bought Instead
Premium
Market News
Cathie Wood Just Sold $3.36M in META Stock. Here’s What She Bought Instead
9d ago
GH
ALMR
Crispr Therapeutics price target lowered to $81 from $82 at BofA
Premium
The Fly
Crispr Therapeutics price target lowered to $81 from $82 at BofA
13d ago
CRSP
Crispr Therapeutics: Favorable Early zugo-cel Data in Systemic Sclerosis Support Buy Rating; $82 Price Target Reiterated
PremiumRatings
Crispr Therapeutics: Favorable Early zugo-cel Data in Systemic Sclerosis Support Buy Rating; $82 Price Target Reiterated
17d ago
CRSP
Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock
PremiumWeekend Updates
Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock
26d ago
GME
CRSP
Claude discovers novel enzyme system with CRISPR-like repeats
PremiumThe Fly
Claude discovers novel enzyme system with CRISPR-like repeats
29d ago
CRSP
Cathie Wood Sells $28.6M of Alphabet Stock and Buys $26.4M of Meta Shares. What Else Is She Buying?
PremiumMarket News
Cathie Wood Sells $28.6M of Alphabet Stock and Buys $26.4M of Meta Shares. What Else Is She Buying?
1M ago
TEM
BEAM
Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321
PremiumThe FlyCiti says Novartis news increases likelihood Crispr prioritizes next-gen CTX321
2M ago
NVS
CRSP
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target
Premium
Ratings
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target
2M ago
CRSP
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
Premium
The Fly
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
2M ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
3M ago
CRSP
Crispr Therapeutics price target lowered to $82 from $83 at BofA
PremiumThe Fly
Crispr Therapeutics price target lowered to $82 from $83 at BofA
3M ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
3M ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
PremiumRatings
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
3M ago
CRSP
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
PremiumRatingsAnalyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
3M ago
CRSP
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Premium
Ratings
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
3M ago
CRSP
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
Premium
Ratings
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
3M ago
CRSP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >